●ASX-READY • COMMERCIAL STAGE • EST. 2001
Precision diagnostics
for the cancers that
still slip through.
Minomic is an Australian molecular diagnostics company
commercialising a blood-based biomarker platform for solid tumours –
starting with prostate, and extending to bladder and pancreatic
cancer. MiCheck® Prostate is reimbursed and shipping today in the US
and Australia.
US Medicare
Reimbursed
PLA code assigned, 2025
Markets live
US + AU
UK/EU signed for 2026
IP portfoli0
40+ assets
Solid-tumour biomarkers
Addressable men
≈ 1M / yr
Elevated-PSA biopsy decisions
Regulated · Reimbursed · In-market with
US CLIA-certified lab Medicare registered Sonic DHM (AU) 20/20 GeneSystems (US) Doc Lab Inc. Macquarie University Hospital
●THE PLATFORM • MiCheck®
A biomarker panel for the moment a urologist must decide.
MiCheck® Prostate is for male patients being considered for a prostate biopsy. It supplements – not replaces – the clinical judgement of the urologist, delivering a clinically significant prostate cancer risk score from a single blood draw.
MiCheck® Prostate · Patient Report
ID · MC-24-00412
Clinically significant prostate cancer — risk score
Recommendation
Consider
biopsy referral
✓ Ease of use
Blood collection made at the same time as the PSA draw — no new workflow.
✓ Clear clinical utility
Single-page, well-defined report that supports the biopsy decision.
✓ Timely delivery
Results ready for the patient's next visit to the clinician.
✓ Dominant health economics
Favourable versus standard of care across payer models.
●THE OPPORTUNITY
A biomarker panel for the moment a urologist must decide.
Prostate biopsy decisions rely on PSA – a test known to over-refer. Precision-diagnostic peers built multi-billion-dollar businesses on solving similar decision points in other tumours. MiCheck® targets the same unmet need in the world’s most-diagnosed male cancer.
US prostate biopsies annually
1.2M+
The majority of which are ultimately negative for clinically significant disease.
Global molecular diagnostics market
$14B
Growing at a double-digit CAGR through the decade.
New US prostate cancer cases (2024)
268K
The most-diagnosed cancer in men – and rising.
●PIPELINE
One platform. A portfolio of solid-tumour programs.
A comprehensive intellectual property portfolio spanning prostate, bladder and pancreatic cancer – each targeting a decision-point with unmet need.
Indication
Asset
Stage
Status
Prostate
MiCheck® Prostate
Commercial · US + AU
Bladder
MiCheck® Bladder
Clinical validation
Pancreatic
MiCheck® Pancreatic
Biomarker discovery
●EXECUTION HISTORY
Six years of regulated, commercial-grade milestones.
2026
2025
2024
2023
2022
2021
●Expert opinion · ASCO GU 2022
“There is a clear, unmet need for a more accurate test to identify the patients who genuinely require a prostate biopsy — and a biomarker panel to support imaging.”
Neal D. Shore, MD, FACS · Prof. Mark Emberton OBE
ASCO Genitourinary Cancers Symposium · University College London
●NEWSROOM
Discover our progress.
For Investors
A commercial
diagnostics
business with a
platform runway.
Request the current investor brief, upcoming milestone calendar
and detailed pipeline dossier.